Roche launches search for new schizophrenia treatment

Roche CEO, Franz B Humer, presenting the company's half-yearly results last year Keystone Archive

The pharmaceuticals group, Roche, and the Icelandic biotechnology company, Decode Genetics, say they are to begin a drug discovery programme to find new treatments and diagnostic tests for schizophrenia.

This content was published on February 14, 2001 - 09:53

The two companies are also to collaborate to create new drugs for the treatment of a disease which causes the narrowing of the arteries.

Decode has identified genes linked to both illnesses. Roche pays Decode for its gene discoveries and has the rights to develop the company's findings into diagnostic products and medicines.

Decode has bought exclusive access to Iceland's health records and is gathering genetic information from the country's population.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.